Due to the longer time before insulin initiation modelled for oral semaglutide compared with empagliflozin and sitagliptin (Fig
Pacheco et al
THE WORLD OF AGONISTS: A New Era in Diabetes, Obesity & Heart-Health Therapies Incretin mimetics especially GLP-1 and GIP agonists are reshaping global healthcare
Your provider may recommend labs or additional assessment depending on your symptoms, health history, and treatment goals
Additionally, different pharmacodynamic effects given the substantially varying biochemical properties and thereby a different effect on appetite, satiety, gastric emptying and insulin compared to the respective GLP-1 analogues are likely causes for the results observed in this study [11, 14, 15]
Common side effects like nausea, vomiting, and diarrhea are usually most pronounced during the initial weeks of treatment and tend to diminish as the body adjusts to the medication